SGLT2 Inhibitors and Chronic Kidney Disease: A Broadening Clinical Perspective

Target Audience

Nephrologists and primary care providers. The secondary audiences are endocrinologists, cardiologists, specialists in internal medicine (MDs and DOs), nurse practitioners, physician assistants, nurses, and pharmacists.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Identify the limitations of current preventive strategies and treatments for CKD, along with the residual need to further reduce associated impacts on CVD and overall mortality risk
Summarize new evidence supporting the impact of SGLT2 inhibitors on the onset and progression of CKD, including conversion to end-stage renal disease (ESRD), in people with and without diabetes
Discuss currently indicated methods to use SGLT2 inhibitors to blunt the progression of CKD, as well as the potential evolution of this usage as additional supportive data are released